Menu
Not yet recruiting NCT07739563

EXERT-BC Cardio: Cardio or Conditioning Training With Breast Cancer

No phase Interventional Cancer Breast Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Resistance Training with Cardio, Resistance Training with Conditioning.
Who it may be relevant to
Registry conditions: Cancer, Breast Cancer. Basic parameters: 20 years — 89 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

EXERT-BC Cardio: Randomized Study of EXErcise Regimens After Treatment for Breast Cancer Utilizing Cardio or Conditioning Training

Overview

In this study, the investigators hypothesize that observed intense resistance training with conditioning elicits similar changes in body composition, muscle mass, and blood pressure as that with cardiovascular training (or cardio) for women treated with breast cancer.

Interventions

  • Behavioral Resistance Training with Cardio
    Participants in this arm will engage in a supervised exercise regimen three times per week, for approximately 2 months (8 weeks). The regimen combines two days of hypertrophy-focused resistance training with a third day dedicated to steady-state cardiovascular exercise. The cardio day will utilize ergometer-based exercises (rowing ergometer, Assault Air Bike) and unweighted sled pushes, with each activity lasting 10 minutes continuously. The overall program aims to improve cardiorespiratory fitn
  • Behavioral Resistance Training with Conditioning
    Participants in this arm will engage in a supervised exercise regimen three times per week, for approximately 2 months (8 weeks). The regimen combines two days of hypertrophy-focused resistance training with a third day dedicated to high-intensity conditioning. The conditioning day involves a circuit format of 6 total exercises, completed for 8 repetitions each across 8 sets, with limited rest periods (10 seconds or less) between exercises and sets. Exercise selection is total-body focused, alte

Primary outcome measures

  • Change in Muscle Mass [Time frame: Baseline (Prior to Program) and At Exercise Program Completion (approximately 2 months).]
  • Change in Fat Mass [Time frame: Baseline (Prior to Program) and At Exercise Program Completion (approximately 2 months).]
Secondary outcome measures (6)
  • Change in Blood Pressure [Time frame: Baseline (Prior to Program), at Month 1, and At Exercise Program Completion (approximately 2 months).]
  • Change in Resting Metabolic Rate [Time frame: At Exercise Program Completion (approximately 2 months).]
  • Change in Body Composition Metrics (Other than Muscle/Fat Mass) [Time frame: Baseline (Prior to Program) and At Exercise Program Completion (approximately 2 months).]
  • Change in Phase Angle [Time frame: Baseline (Prior to Program) and At Exercise Program Completion (approximately 2 months).]
  • Exercise Adherence [Time frame: Throughout the Exercise Program (approximately 2 months).]
  • Change in Grip Strength [Time frame: Baseline (Prior to Program), During Exercise Program (before and after each workout), and At Exercise Program Completion (approximately 2 months).]

Eligibility criteria

Inclusion criteria

  • Age 20-89 years
  • Women prescribed exercise as a SOC
  • Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
  • Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
  • Women with > 3 months of resistance training experience under expert guidance by a CSCS
  • Must be able to read and understand English and consent for themselves.

Exclusion criteria

  • Any current treatment with cytotoxic chemotherapy for breast cancer
  • Inability to safely engage in group sessions of resistance training as deemed by study PI
  • Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
  • Beta blocker or GLP-1 inhibitor medications
  • Pregnant women
  • Males

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

United States · 1 center
  • AHN Allegheny General Hospital — Pittsburgh

Identifiers

NCT: NCT07739563 · 2026-195

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗